Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Csl Ltd ADR (CSLLY)

Csl Ltd ADR (CSLLY)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
82.6200 +1.8500 (+2.29%) 02/18/25 [OTC US]
N/A x N/A N/A x N/A
Post-market 82.6200 unch (unch) 16:00 ET
Quote Overview for Tue, Feb 18th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
82.2300
Day High
83.5700
Open 83.5300
Previous Close 80.7700 80.7700
Volume 249,600 249,600
Avg Vol 89,920 89,920
Stochastic %K 32.60% 32.60%
Weighted Alpha -15.95 -15.95
5-Day Change -1.9700 (-2.33%) -1.9700 (-2.33%)
52-Week Range 77.3700 - 109.0000 77.3700 - 109.0000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 78,218,712
  • Shares Outstanding, K 968,413
  • Annual Sales, $ 14,800 M
  • Annual Income, $ 2,642 M
  • EBIT $ 0 M
  • EBITDA $ 4,750 M
  • 60-Month Beta 0.75
  • Price/Sales 5.28
  • Price/Cash Flow 20.29
  • Price/Book 4.02
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/12/24
  • Annual Dividend & Yield 1.22 (1.51%)
  • Most Recent Dividend 0.675 on 09/10/24
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
77.3700 +6.79%
on 02/12/25
Period Open: 86.1600
89.6900 -7.88%
on 01/30/25
-3.5400 (-4.11%)
since 01/17/25
3-Month
77.3700 +6.79%
on 02/12/25
Period Open: 88.2900
94.9800 -13.01%
on 11/26/24
-5.6700 (-6.42%)
since 11/18/24
52-Week
77.3700 +6.79%
on 02/12/25
Period Open: 92.6100
109.0000 -24.20%
on 08/28/24
-9.9900 (-10.79%)
since 02/16/24

Most Recent Stories

More News
New Strong Sell Stocks for February 12th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Ares Management Corporation ARES is an alternative asset manager. The Zacks Consensus Estimate for its current year earnings has...

ARES : 187.67 (+0.80%)
CABGY : 23.9800 (-0.70%)
CSLLY : 82.6200 (+2.29%)
3 Pharma Stocks to Buy as California Sounds the Alarm on Bird Flu Cases

The bird flu crisis is creating investment opportunities in the pharmaceutical sector, with Sanofi, GSK, and CSL Limited emerging as top picks.

GSK : 36.61 (+1.22%)
CSLLY : 82.6200 (+2.29%)
SNY : 53.95 (-1.01%)
CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

/PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) (USOTC: CSLLY) announced today that Jeffrey Ball, an established global leader across multiple...

CSL : 354.99 (-0.51%)
CSLLY : 82.6200 (+2.29%)
Why CSL Ltd Stock Could Be Worth a Look

FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment.

CSL : 354.99 (-0.51%)
CSLLY : 82.6200 (+2.29%)
NVS : 106.61 (+1.12%)
BLUE : 7.12 (-2.06%)
ARCT : 17.71 (-1.88%)
Why Arcturus Therapeutics Stock Is Skyrocketing Today

Investors are applauding Arcturus' collaboration with CSL.

CSL.AX : 264.850 (+0.39%)
CSLLY : 82.6200 (+2.29%)
ARCT : 17.71 (-1.88%)
Finalization of Vifor Pharma acquisition

Regulatory News:

CSL.AX : 264.850 (+0.39%)
OTC.VN : 0.300 (-6.25%)
CSLLY : 82.6200 (+2.29%)
uniQure announces closing of commercialization and license agreement with CSL Behring

Upfront payment of $450 million due to uniQure by May 13, 2021

CSLLY : 82.6200 (+2.29%)
ASX : 11.03 (+1.38%)
QURE : 13.25 (-6.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions. The company's operating segments consists of CSL Behring and bioCSL. CSL Behring segment provides plasma-derived...

See More

Key Turning Points

3rd Resistance Point 84.7233
2nd Resistance Point 84.1467
1st Resistance Point 83.3833
Last Price 82.6200
1st Support Level 82.0433
2nd Support Level 81.4667
3rd Support Level 80.7033

See More

52-Week High 109.0000
Fibonacci 61.8% 96.9173
Fibonacci 50% 93.1850
Fibonacci 38.2% 89.4527
Last Price 82.6200
52-Week Low 77.3700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Increase Profitable Opportunities with Barchart's Technical Opinion